VanEck Associates’s Puma Biotechnology PBYI Stock Holding History

VanEck Associates’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-19,237	Closed	-$573K	–	880
2016 Q2	$573K	Sell	19,237 -20,382	-51%	-$637K	﹤0.01%	534
2016 Q1	$1.16M	Buy	39,619 +5,163	+15%	+$233K	0.01%	420
2015 Q4	$2.7M	Buy	34,456 +1,047	+3%	+$82.2K	0.02%	283
2015 Q3	$2.52M	Sell	33,409 -16,716	-33%	-$1.58M	0.02%	297
2015 Q2	$5.85M	Buy	50,125 +867	+2%	+$157K	0.03%	246
2015 Q1	$11.6M	Sell	49,258 -6,617	-12%	-$1.41M	0.07%	194
2014 Q4	$10.6M	Buy	55,875 +5,515	+11%	+$1.22M	0.07%	197
2014 Q3	$12M	Buy	+50,360	New	+$10.3M	0.06%	184

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VanEck Associates's PBYI Position: Q3 2016 in Review

VanEck Associates sold out of Puma Biotechnology (PBYI) in Q3 2016, closing a stake of 19,237 shares — an estimated $573K sold.

VanEck Associates first reported a position in PBYI in Q3 2014 and held it in 8 quarters. The position peaked at $12M in Q3 2014. 149 funds tracked by Wall St. Rank hold PBYI as of Q3 2016.

VanEck Associates reported no remaining Puma Biotechnology position as of Q3 2016 after selling out during the quarter.
VanEck Associates sold 19,237 Puma Biotechnology shares in Q3 2016, an estimated $573K.
VanEck Associates first reported a position in Puma Biotechnology in Q3 2014 and held it in 8 quarters.
VanEck Associates's Puma Biotechnology position peaked at $12M in Q3 2014.
149 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2016.

Based on VanEck Associates's 13F filing for Q3 2016, filed 14 Nov 2016.